Axsome Therapeutics (AXSM) Non-cash Items (2016 - 2026)

Axsome Therapeutics has disclosed Non-cash Items across 11 years of filings, most recently posting $5.2 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $5.2 million, down 3.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (down 3.97% YoY), and the FY2025 annual result was $5.3 million, down 1.08% from the prior year.
• Non-cash Items came in at $5.2 million for Q1 2026 at Axsome Therapeutics, down from $5.3 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $160.9 million in Q3 2024 to a low of $264781.0 in Q2 2023.
• The 5-year median for Non-cash Items is $5.3 million (2025), against an average of $36.9 million.
• Across the five-year window, Non-cash Items tumbled 99.71% in 2023 and jumped 3736.84% in 2024, its largest moves.
• Axsome Therapeutics' Non-cash Items stood at $95.7 million in 2022, then plunged by 99.66% to $323159.0 in 2023, then surged by 1561.25% to $5.4 million in 2024, then fell by 1.08% to $5.3 million in 2025, then fell by 1.79% to $5.2 million in 2026.
• The last three Non-cash Items figures came in at $5.2 million (Q1 2026), $5.3 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.